{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:10:46Z","timestamp":1776417046392,"version":"3.51.2"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11060-021-03924-2","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:03:46Z","timestamp":1642637026000},"page":"443-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Leptomeningeal metastases: the future is now"],"prefix":"10.1007","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-5396","authenticated-orcid":false,"given":"Rimas V.","family":"Lukas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigisha P.","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunandana","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej S.","family":"Lesniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"3924_CR1","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.jns.2020.116706","volume":"411","author":"JP Thakkar","year":"2020","unstructured":"Thakkar JP, Kumthekar P, Dixit KS, Stupp R, Lukas RV (2020) Leptomeningeal metastasis from solid tumors. J Neurol Sci 411:116706","journal-title":"J Neurol Sci"},{"issue":"18","key":"3924_CR2","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74(18):1449\u20131454","journal-title":"Neurology"},{"key":"3924_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","volume":"56","author":"JW Hyun","year":"2016","unstructured":"Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ (2016) Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 56:107\u2013114","journal-title":"Eur J Cancer"},{"issue":"10","key":"3924_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","volume":"29","author":"JP Glass","year":"1979","unstructured":"Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29(10):1369\u20131375","journal-title":"Neurology"},{"issue":"9","key":"3924_CR5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","volume":"23","author":"N Lamba","year":"2021","unstructured":"Lamba N, Wen PY, Aizer AA (2021) Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol 23(9):1447\u20131456","journal-title":"Neuro Oncol"},{"issue":"Suppl_4","key":"3924_CR6","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Ruhn","year":"2017","unstructured":"Le Ruhn E, Weller M, Brandsma D et al (2017) EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of patients with leptomeningeal metastasis from solid tumors. Ann Oncol 28(Suppl_4):iv84\u2013iv99","journal-title":"Ann Oncol"},{"issue":"4","key":"3924_CR7","first-page":"484","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D et al (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 19(4):484\u2013492","journal-title":"Neuro Oncol"},{"issue":"5","key":"3924_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/neuonc\/noz208","volume":"22","author":"KS Nevel","year":"2020","unstructured":"Nevel KS, DiStefano N, Lin X et al (2020) A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. Neuro Oncol 22(5):675\u2013683","journal-title":"Neuro Oncol"},{"issue":"5","key":"3924_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/neuonc\/noz024","volume":"21","author":"E Le Ruhn","year":"2019","unstructured":"Le Ruhn E, Devos P, Boulanger T et al (2019) The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol 21(5):648\u2013658","journal-title":"Neuro Oncol"},{"issue":"1","key":"3924_CR10","first-page":"42","volume":"3","author":"MS Chamberlian","year":"2001","unstructured":"Chamberlian MS, Kormanik PA, Glantz MJ (2001) A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 3(1):42\u201345","journal-title":"Neuro Oncol"},{"issue":"Suppl2","key":"3924_CR11","doi-asserted-by":"publisher","first-page":"ii7","DOI":"10.1093\/noajnl\/vdaa073.028","volume":"2","author":"M Weller","year":"2020","unstructured":"Weller M, Le Ruhn E (2020) 40. An update on the development of a new tool to assess response in leptomeningeal metastasis. Neuro Oncol Adv 2(Suppl2):ii7","journal-title":"Neuro Oncol Adv"},{"issue":"5","key":"3924_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/neuonc\/noz012","volume":"21","author":"A Boire","year":"2019","unstructured":"Boire A, Brandsma D, Brastianos PK et al (2019) Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol 21(5):571\u2013584","journal-title":"Neuro Oncol"},{"issue":"5","key":"3924_CR13","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1212\/WNL.0000000000008751","volume":"94","author":"MTJ Van Bussel","year":"2020","unstructured":"Van Bussel MTJ, Pluim D, Milojkovic Kerklaan B et al (2020) Circulating epithelial cell analysis in CSF in patients with leptomeningeal metastases. Neurology 94(5):e521\u2013e528","journal-title":"Neurology"},{"key":"3924_CR14","doi-asserted-by":"crossref","unstructured":"Angus L, Deger T, Jager A, et al (2021) Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases. Clin Cancer Res. [EPub ahead of print]","DOI":"10.1158\/1078-0432.CCR-20-3954"},{"issue":"32","key":"3924_CR15","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J et al (2020) Survival in patients with brain metastases: summary report of the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 38(32):3773\u20133784","journal-title":"J Clin Oncol"},{"key":"3924_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.clineuro.2018.03.008","volume":"168","author":"Y Murakami","year":"2018","unstructured":"Murakami Y, Ichikawa M, Bakhit M et al (2018) Palliative shunt surgery for patients with leptomeningeal metastases. Clin Neurol Neurosurg 168:175\u2013178","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"3924_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11060-010-0512-2","volume":"104","author":"SH Lee","year":"2011","unstructured":"Lee SH, Kong DS, Seol HJ, Nam DH, Lee JI (2011) Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol 104(2):545\u2013551","journal-title":"J Neurooncol"},{"key":"3924_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clineuro.2014.01.023","volume":"119","author":"TY Jung","year":"2014","unstructured":"Jung TY, Chung WK, Oh IJ (2014) The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosurg 119:80\u201383","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"3924_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim SW, Kim DW et al (2020) Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 38(6):538\u2013547","journal-title":"J Clin Oncol"},{"issue":"10","key":"3924_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","volume":"31","author":"S Park","year":"2020","unstructured":"Park S, Lee MH, Seong M et al (2020) A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 31(10):1397\u20131404","journal-title":"Ann Oncol"},{"issue":"13","key":"3924_CR21","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","volume":"25","author":"A Morikawa","year":"2019","unstructured":"Morikawa A, de Stanchina E, Pentsova E et al (2019) Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases. Clin Cancer Res 25(13):3784\u20133792","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3924_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","volume":"78","author":"AB Lassman","year":"2006","unstructured":"Lassman AB, Abrey LE, Shah GD et al (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78(3):255\u2013260","journal-title":"J Neurooncol"},{"issue":"5","key":"3924_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clbc.2019.04.004","volume":"19","author":"MM Mrugala","year":"2019","unstructured":"Mrugala MM, Kim B, Sharma A et al (2019) Phase II study of systemic high-dose methotrexate and intrathecal liposomal cytarabine for treatment of leptomeningeal carcinomatosis from breast cancer. Clin Breast Cancer 19(5):311\u2013316","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"3924_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11060-013-1055-0","volume":"112","author":"P Kumthekar","year":"2013","unstructured":"Kumthekar P, Grimm SA, Avram MJ et al (2013) Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J Neurooncol 112(2):247\u2013255","journal-title":"J Neurooncol"},{"issue":"8","key":"3924_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/jcm7080216","volume":"7","author":"MC Burger","year":"2018","unstructured":"Burger MC, Wagner M, Franz K et al (2018) Ventriculoperitoneal shunts equipped with on-off valves for intraventricular therapies in patients with communicating hydrocephalus due to leptomeningeal metastases. J Clin Med 7(8):216","journal-title":"J Clin Med"},{"issue":"2","key":"3924_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1215\/15228517-2007-059","volume":"10","author":"MD Groves","year":"2008","unstructured":"Groves MD, Glantz MJ, Chamberlain MC et al (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208\u2013215","journal-title":"Neuro Oncol"},{"issue":"1","key":"3924_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/JCO.2003.04.053","volume":"21","author":"SM Blaney","year":"2003","unstructured":"Blaney SM, Heideman R, Berg S et al (2003) Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21(1):143\u2013147","journal-title":"J Clin Oncol"},{"issue":"9","key":"3924_CR28","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/cncr.21828","volume":"106","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S et al (2006) Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106(9):2021\u20132027","journal-title":"Cancer"},{"issue":"8","key":"3924_CR29","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L et al (2021) Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptoeningeal metastases from EGFR-mutant NSCLC, a prospective, open-label, single-arm phase 1\/2 clinical trial (Unique identifier: ChiCTR1800016615). J Thorac Oncol 16(8):1359\u20131368","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3924_CR30","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394\u20133402","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3924_CR31","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1345\/aph.1P197","volume":"44","author":"AJ Perissinotti","year":"2010","unstructured":"Perissinotti AJ, Reeves DJ (2010) Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother 44(10):1633\u20131640","journal-title":"Ann Pharmacother"},{"issue":"2","key":"3924_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-018-4684-3","volume":"169","author":"NB Figura","year":"2018","unstructured":"Figura NB, Long W, Yu M et al (2018) Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat 169(2):391\u2013396","journal-title":"Breast Cancer Res Treat"},{"key":"3924_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","volume":"95","author":"C Bonneau","year":"2018","unstructured":"Bonneau C, Paintaud G, Tredan O et al (2018) Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 95:75\u201384","journal-title":"Eur J Cancer"},{"issue":"2","key":"3924_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4143\/crt.2014.234","volume":"48","author":"WY Park","year":"2016","unstructured":"Park WY, Kim HJ, Kim K et al (2016) Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res Treat 48(2):843\u2013847","journal-title":"Cancer Res Treat"},{"issue":"11","key":"3924_CR35","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","volume":"19","author":"O Mir","year":"2008","unstructured":"Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19(11):1978\u20131980","journal-title":"Ann Oncol"},{"key":"3924_CR36","doi-asserted-by":"crossref","unstructured":"Law V, Baldwin M, Ramamoorthi G, et al (2021) A murine Ommya xenograft model to study direct-targeted therapy of leptomeningeal disease. J Vis Exp. (167)","DOI":"10.3791\/62033"},{"issue":"4","key":"3924_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJM197507242930402","volume":"293","author":"WR Shapiro","year":"1975","unstructured":"Shapiro WR, Young DF, Posner JB (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293(4):161\u2013166","journal-title":"N Engl J Med"},{"key":"3924_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fonc.2018.00509","volume":"8","author":"M de Oca","year":"2018","unstructured":"de Oca M, Delgado M, Cacho Diaz B, Santos Zambrano J et al (2018) The comparative treatment of intraventricular chemotherapy vs lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol 8:509","journal-title":"Front Oncol"},{"key":"3924_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fonc.2018.00641","volume":"8","author":"RA El Shafie","year":"2018","unstructured":"El Shafie RA, Bohm K, Weber D et al (2018) Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome, prognostic factors, and symptom response. Front Oncol 8:641","journal-title":"Front Oncol"},{"issue":"3","key":"3924_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1212\/01.WNL.0000106941.51340.A2","volume":"62","author":"R Lai","year":"2004","unstructured":"Lai R, Abrey LE, Rosenblum MK, DeAngelis LM (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62(3):451\u2013456","journal-title":"Neurology"},{"issue":"1","key":"3924_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","volume":"23","author":"TJ Yang","year":"2020","unstructured":"Yang TJ, Wijetunga NA, Yamada J et al (2020) Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol 23(1):134\u2013143","journal-title":"Neuro Oncol"},{"key":"3924_CR42","unstructured":"Ron DA, Labandeira CM, Manrique MCA, et al. Dramatic response of leptomeningeal carcinomatosis to nivolumab in PD-L1 highly expressive non-small cell lung cancer: a case report. Front Oncol. 20"},{"issue":"3421","key":"3924_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133(3421):571\u2013573","journal-title":"Lancet"},{"key":"3924_CR44","doi-asserted-by":"crossref","unstructured":"Remsik J, Chi Y, Tong X, et al (2020) Leptomeningeal metastatic cells adopt two phenotypic states. Cancer Rep. e1236","DOI":"10.1002\/cnr2.1236"},{"key":"3924_CR45","doi-asserted-by":"crossref","unstructured":"Raizer J, Pentsova E, Omuro A, et al (2014) Phase 1 tria of intrathecal trastuzumab in HER2 positive leptomeningeal metastases. AT-47. Neuro Onco. 16(Supp 5):v19","DOI":"10.1093\/neuonc\/nou237.46"},{"issue":"7","key":"3924_CR46","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1212\/01.wnl.0000178981.39984.c2","volume":"65","author":"JC Reijneveld","year":"2005","unstructured":"Reijneveld JC, Brandsma D, Boogerd W et al (2005) CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 65(7):1120\u20131122","journal-title":"Neurology"},{"issue":"9","key":"3924_CR47","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-19-2840","volume":"26","author":"I Smalley","year":"2020","unstructured":"Smalley I, Law V, Wyatt C et al (2020) Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance. Clin Cancer Res 26(9):2163\u20132175","journal-title":"Clin Cancer Res"},{"issue":"6501","key":"3924_CR48","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1126\/science.aaz2193","volume":"369","author":"Y Chi","year":"2020","unstructured":"Chi Y, Remsik J, Kiseliovas V et al (2020) Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science 369(6501):276\u2013282","journal-title":"Science"},{"issue":"6","key":"3924_CR49","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","volume":"168","author":"A Boire","year":"2017","unstructured":"Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massague J (2017) Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168(6):1101-1113.e13","journal-title":"Cell"},{"issue":"3","key":"3924_CR50","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11060-020-03555-z","volume":"148","author":"R Malani","year":"2020","unstructured":"Malani R, Fleischer M, Kumthekar P et al (2020) Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J Neurooncol 148(3):599\u2013606","journal-title":"J Neurooncol"},{"issue":"18","key":"3924_CR51","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-17-0047","volume":"23","author":"BY Jiang","year":"2017","unstructured":"Jiang BY, Li YS, Guo WB et al (2017) Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next \u2013generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res 23(18):5480\u20135488","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3924_CR52","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","volume":"19","author":"X Lin","year":"2017","unstructured":"Lin X, Fleisher M, Rosenblum M et al (2017) Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro Oncol 19(9):1248\u20131254","journal-title":"Neuro Oncol"},{"issue":"15_suppl","key":"3924_CR53","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2021.39.15_suppl.2011","volume":"39","author":"NA Wijetunga","year":"2021","unstructured":"Wijetunga NA, Boire AA, Yamada Y et al (2021) Cerebrospinal fluid circulating tumor cells as a predictive biomarker for proton craniospinal irradiation for leptomeningeal metastases. J Clin Oncol 39(15_suppl):2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"3924_CR54","first-page":"00065","volume":"S1525\u20131578","author":"TA Bale","year":"2021","unstructured":"Bale TA, Yang SR, Solomon JP et al (2021) Clinical experience of cerebrospinal fluid \u2013based liquid biopsy demonstrates superiority of cell-free DNA over cell-pellet genomic DNA for molecular profiling. J Mol Diagn S1525\u20131578(21):00065\u201300069","journal-title":"J Mol Diagn"},{"issue":"2","key":"3924_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jtho.2020.10.008","volume":"16","author":"MM Zheng","year":"2021","unstructured":"Zheng MM, Li YS, Tu HY et al (2021) Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC. J Thorac Oncol 16(2):250\u2013258","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3924_CR56","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","volume":"26","author":"P Kumthekar","year":"2020","unstructured":"Kumthekar P, Tang SC, Brenner AJ et al (2020) ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and brain metastases. Clin Cancer Res 26(12):2789\u20132799","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3924_CR57","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379(8):722\u2013730","journal-title":"N Engl J Med"},{"key":"3924_CR58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM, Lukas RV, Goldschmidt J et al (2019) Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer 128:105\u2013112","journal-title":"Lung Cancer"},{"issue":"5","key":"3924_CR59","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldeberg","year":"2020","unstructured":"Goldeberg SB, Schalper KA, Gettinger SN et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysisfrom a non-randomised, open-label, phase 2 trial. Lancet Oncol 21(5):655\u2013663","journal-title":"Lancet Oncol"},{"issue":"8","key":"3924_CR60","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos PK, Lee EQ, Cohen JV et al (2020) Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 26(8):1280\u20131284","journal-title":"Nat Med"},{"key":"3924_CR61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","volume":"98","author":"E Dudnik","year":"2016","unstructured":"Dudnik E, Yust-Katz S, Nechushtan H et al (2016) Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 98:114\u2013117","journal-title":"Lung Cancer"},{"key":"3924_CR62","doi-asserted-by":"crossref","unstructured":"Bonomi L, Bettini AC, Arnoldi E, et al (2020) Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: a case report. Tumori. 106(6):NP76-NP78","DOI":"10.1177\/0300891620904411"},{"issue":"10","key":"3924_CR63","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-14-2280","volume":"21","author":"LG Lum","year":"2015","unstructured":"Lum LG, Thakur A, Al-Kadhimi Z et al (2015) Targted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res 21(10):2305\u20132314","journal-title":"Clin Cancer Res"},{"key":"3924_CR64","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A et al (2020) Tucatinib, trastuzumab, and capecitabine for HER1-positive metastatic breast cancer. N Engl J Med 382:597\u2013609","journal-title":"N Engl J Med"},{"issue":"558","key":"3924_CR65","doi-asserted-by":"publisher","first-page":"eaax2879","DOI":"10.1126\/scitranslmed.aax2879","volume":"12","author":"D Kanojia","year":"2020","unstructured":"Kanojia D, Panek WK, Cordero A et al (2020) BET inhibition increases \u03b2III-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine. Sci Transl Med. 12(558):eaax2879","journal-title":"Sci Transl Med."},{"key":"3924_CR66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste Y (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125","journal-title":"N Engl J Med"},{"issue":"2","key":"3924_CR67","first-page":"e46","volume":"48","author":"HS Teh","year":"2007","unstructured":"Teh HS, Fadilah SA, Leong CF (2007) Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J 48(2):e46\u2013e49","journal-title":"Singapore Med J"},{"key":"3924_CR68","doi-asserted-by":"publisher","first-page":"117955571880907","DOI":"10.1177\/1179555718809071","volume":"11","author":"H Tariq","year":"2018","unstructured":"Tariq H, Gilbert A, Sharkey FE (2018) Intrathecal Methotrexate-Induced Necrotizing Myelopathy: A Case Report and Review of Histologic Features. Clin Med Insights Pathol 11:1179555718809071","journal-title":"Clin Med Insights Pathol"},{"issue":"1","key":"3924_CR69","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11060-012-0880-x","volume":"109","author":"MC Chamberlain","year":"2012","unstructured":"Chamberlain MC (2012) Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol 109(1):143\u2013148","journal-title":"J Neurooncol"},{"key":"3924_CR70","doi-asserted-by":"publisher","first-page":"4047617","DOI":"10.1155\/2019\/4047617","volume":"2019","author":"DM Byrnes","year":"2019","unstructured":"Byrnes DM, Vargas F, Dermarkarian C et al (2019) Complications of intrathecal chemotherapy in adults: single-institution experience in 109 consecutive patients. J Oncol 2019:4047617","journal-title":"J Oncol"},{"issue":"5","key":"3924_CR71","first-page":"611","volume":"41","author":"R Olmos-Jimenez","year":"2017","unstructured":"Olmos-Jimenez R, Diaz-Carrasco MS, Cabanas-Perianes V, Valderrey-Pulido M, Espuny-Miro A (2017) Evaluation of standardized triple intrathecal therapy toxicity in oncohematological adult patients. Farm Hosp 41(5):611\u2013617","journal-title":"Farm Hosp"},{"issue":"4","key":"3924_CR72","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3340\/jkns.2011.50.4.304","volume":"50","author":"JY Kim","year":"2011","unstructured":"Kim JY, Kim ST, Nam DH, Lee JI, Park K, Kong DS (2011) Leukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia. J Korean Neurosurg Soc 50(4):304\u2013310","journal-title":"J Korean Neurosurg Soc"},{"issue":"10","key":"3924_CR73","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/jnnp.51.10.1277","volume":"51","author":"W Boogerd","year":"1988","unstructured":"Boogerd W, vd Sande JJ, Moffie D, (1988) Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51(10):1277\u20131283","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03924-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03924-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03924-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T08:08:31Z","timestamp":1676102911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03924-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3924"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03924-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}